Chronic Incomplete Cervical Spinal Cord Injury (SCI)

0
Pipeline Programs
2
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
1 program
Transcutaneous Auricular Vagus Nerve StimulationN/A
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
Transcutaneous Auricular Vagus Nerve StimulationN/A1 trial
Active Trials
NCT06543277Recruiting12Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
Mission TherapeuticsTranscutaneous Auricular Vagus Nerve Stimulation

Clinical Trials (1)

Total enrollment: 12 patients across 1 trials

NCT06543277Mission TherapeuticsTranscutaneous Auricular Vagus Nerve Stimulation

Safety and Feasibility of Paired Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) With Upper Limb Rehabilitation in Incomplete Spinal Cord Injury

Start: Aug 2025Est. completion: Dec 202712 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 12 patients
2 companies competing in this space